NCT02390427 2026-04-09
Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
Clinical Trials
7 trialsNCT04253561 2026-03-16
IPATHER
SOLTI Breast Cancer Research Group
Phase 1 Completed
NCT03006172 2026-03-11
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Genentech, Inc.
Phase 1 Active not recruiting
NCT02057133 2026-01-26
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
Eli Lilly and Company
Phase 1 Active not recruiting
NCT03716180 2025-09-22
DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT05385705 2025-09-22
A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020
Vall d'Hebron Institute of Oncology
Phase 1 Terminated
NCT04188548 2025-06-04
EMBER
Eli Lilly and Company
Phase 1 Active not recruiting